Changes in fatigue and life participation ratings in the intervention versus control groups
| Domain | Measure | Study arm | Baseline median score (IQR) | 1-week post-treatment follow-up | 12-week post-treatment follow-up | ||||
| Median score (IQR) | Median change from baseline (IQR) | Hedge’s G effect size estimate | Median score (IQR) | Median change from baseline (IQR) | Hedge’s G effect size estimate | ||||
| Life participation | COPM-P | Control | 4.3 (3.7, 7.7) | 4.7 (2.5, 7.8) | −0.3 (−1.8, +1.0) | 0.62 Medium | 4.3 (1.7, 5.3) | +0.3 (−2.0, +1.3) | 0.90 Large |
| Treatment | 4.7 (4.0, 6.7) | 5.3 (4.7, 6.7) | +1.3 (+0.3, +1.7) | 6.8 (5.4, 7.6) | +1.9 (0.0, +3.5) | ||||
| COPM-S | Control | 4.0 (2.3, 8.0) | 6.0 (3.0, 8.0) | +0.3 (−0.8, +2.0) | 0.13 Very small | 4.0 (1.0, 5.0) | 0.0 (−2.0, +0.7) | 1.36 Very large | |
| Treatment | 4.0 (3.3, 5.3) | 5.3 (3.8, 6.5) | +0.7 (−0.3, +1.8) | 6.7 (4.9, 7.5) | +1.8 (+1.4, +3.1) | ||||
| FMQ- Global LP | Control | 6.0 (4.7, 7.0) | 6.5 (4.8, 8.1) | 0.0 (−1.4, +2.4) | 0.50 Medium | 5.6 (3.0, 8.0) | −0.4 (−2.0, +1.0) | 0.16 Very small | |
| Treatment | 4.7 (3, 6.3) | 6.3 (5.8, 7.4) | +1.8 (+0.5, +2.1) | 5 (2.25, 5.75) | +1.0 (−2.0, +4.0) | ||||
| FMQ- Global LPS | Control | 5.0 (4.0, 8) | 7.5 (4.5, 9.0) | +1.0 (−1.3, +3.3) | 0.50 Medium | 6.0 (4.0, 7.5) | 0.0 (−2.0, +1.0) | 0.16 Very small | |
| Treatment | 4.0 (2.0, 5.0) | 7.0 (4.5, 8.3) | +4.0 (+0.5, +5.3) | 4.5 (2.25, 5.75) | 0.0 (−2.0, +4.0) | ||||
| RNLI | Control | 78 (51, 88) | 81.0 (58.0, 94.0) | −1.0 (−5.0, +15.0) | Favours control | 83 (60, 101) | +5.5 (−7.5, +24.0) | Favours control | |
| Treatment | 71 (56, 83) | 61.5 (51.5, 78.8) | −3.0 (−10.0, +11.3) | 61.5 (50.5, 78.5) | −1.0 (−20.0, +12.8) | ||||
| Fatigue | FSS | Control | 5.0 (4.3, 6.1) | 4.3 (3.8, 5.9) | −0.3 (−1.1, +1.0) | 0.36 Small | 4.0 (2.7, 4.9) | −1.1 (−1.8, –3.5) | Favours control |
| Treatment | 6.0 (5.6, 6.3) | 5.3 (4.4, 6.0) | −0.6 (−1.9, +0.2) | 5.2 (4.1, 6.0) | −0.8 (−1.0, 0.0) | ||||
| MFIS | Control | 50.0 (38, 55) | 39.5 (29.5, 49.3) | −6.5 (−23, +0.5) | Favours control | 29 (22.5, 49.5) | −12.0 (−20.0, –6.5) | Favours control | |
| Treatment | 52.0 (45, 59) | 48 (38.5, 51.5) | −8.0 (−13, +1.5) | 47.5 (39.0, 65.0) | −1.0 (−10.0, +12.0) | ||||
| SONG-HD Fatigue | Control | 6.0 (4.0, 7.0) | 4.5 (3.3, 7.0) | 0.0 (−2.0, 0.0) | 0.15 Very small | 5.0 (3.25, 6.0) | −1.0 (−2.0, +1.0) | Favours control | |
| Treatment | 6.0 (3.8, 9) | 5.0 (3.8, 6.0) | −1.0 (−4.5, +2.5) | 6.0 (5.0, 6.0) | 0.0 (−1.0, +3.0) | ||||
| Self-efficacy | Control | 5.0 (5.0, 8.0) | 6.2 (5.0, 9.0) | +0.2 (−1.0, +3.3) | 0.50 Medium | 8.0 (4.5, 9.0) | 0.0 (−1.0, +3.0) | 0.02 Very small | |
| Treatment | 4.0 (2.0, 5.0) | 6.5 (4.3, 7.3) | +3.0 (−0.0, +3.0) | 5.0 (3.0, 5.0) | +0.5 (−1.5, +3.0) | ||||
*Values expressed are medians (IQRs).
COPM-P, Canadian Occupational Performance Measure-Performance Scale; COPM-S, Canadian Occupational Performance Measure-Satisfaction Scale; FMQ, Fatigue Management Questionnaire; FSS, Fatigue Severity Scale; Global LP, Global Life Participation; Global LPS, Global Life Participation Satisfaction; MFIS, Modified Fatigue Impact Scale; RNLI, Reintegration to Normal Living Index; SONG-HD Fatigue, Standardised Outcomes in Nephrology-Haemodialysis Fatigue.